Dallas, TX, United States of America

Tissuegen, Inc.


USPTO Granted Patents = 5



Forward Citations = 8

Loading Chart...
Loading Chart...

14 inventors (with patents filed for the assignee):

goldMedal Brent B Crow (4 out of 6 patents)

silverMedal Kevin D Nelson (4 out of 10 patents)

bronzeMedal Jennifer Seifert (3 out of 3 patents)

4.  Paul R Sood (3 out of 5 patents)

5.  Nickolas B Griffin (3 out of 3 patents)

6.  Alpeshkumar P Patel (3 out of 3 patents)

7.  Paul A Hubbard (2 out of 2 patents)

8.  William L D'Agostino (1 out of 10 patents)

9.  Lev Drubetsky (1 out of 18 patents)

10.  Alexander Naimagon (1 out of 14 patents)

11.  Rui Avelar (1 out of 5 patents)

12.  Paula J Taylor (1 out of 1 patent)

13.  Ryszard Zarzycki (1 out of 5 patents)

14.  Jeffrey Mendel Gross (1 out of 63 patents)

15.  William L D'agostino (0 patent)


5 patents:

Company Overview
Tissuegen, Inc. is a biotechnology company focused on developing and commercializing regenerative medicine and drug delivery solutions. The company's patented technology allows for the controlled release of therapeutic agents within the body, enabling targeted drug delivery and tissue regeneration. With a commitment to advancing medical innovation, Tissuegen is dedicated to improving patient outcomes and quality of life.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

5 Patents

#369 in Dallas, TX

#3,331 in Texas

#51,620 in US

Dallas, TX (US)
Dallas, TX, United States of America
Forward Citations = 8

14 inventors:

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Tissuegen, Inc.. Retrieved from https://idiyas.com/company/tissuegen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…